Intravenous Tramadol Dosing Regimen for Post-Surgical Pain
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for managing post-surgical acute pain, particularly in patients unable to take oral medications, lack effective alternatives that provide rapid onset and reduced side effects such as nausea and seizures, and are not opioid-sparing.
Innovation Solution
An intravenous dosing regimen for tramadol involving initial doses of 25-50 mg administered at 0, 2, and 4 hours, followed by 25 mg every 4 hours, aiming to achieve plasma concentrations similar to a 50 mg oral tramadol dose given every 6 hours, thereby providing effective pain relief with reduced side effects and opioid-sparing benefits.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of intravenous tramadol (50-100 mg every 4-6 hours) are administered to achieve effective pain relief, then analgesic efficacy is improved, but peak-to-trough concentration fluctuation increases leading to more side effects like nausea and seizures
Solution Approach 1:
The patent divides the dosing regimen into an initial loading phase (0, 2, and 4 hours) followed by a maintenance phase (every 4 hours), segmenting the total daily dose into more frequent smaller administrations to reduce peak-to-trough fluctuations while maintaining effective pain relief
Solution Approach 2:
The patent changes the dosing parameters from standard 50-100 mg every 4-6 hours to 25-50 mg at specific intervals (0, 2, 4 hours initially, then every 4 hours), optimizing the concentration-time profile to maintain therapeutic levels while minimizing toxic peaks
2Speed
If standard intravenous tramadol dosing (50-100 mg every 4-6 hours) is used, then rapid onset of action is achieved, but the regimen is not opioid-sparing and requires high cumulative doses
Solution Approach 1:
The patent administers initial loading doses at 0, 2, and 4 hours to rapidly achieve therapeutic plasma concentrations and steady-state levels, providing immediate and sustained pain relief without requiring high cumulative doses throughout the 48-hour period
3Reliability
If patients receive intravenous tramadol for postoperative pain, then effective analgesia is provided, but nausea and seizures remain significant side effects that limit tolerability
Solution Approach 1:
The patent employs periodic intravenous administration at optimized intervals (initially every 2 hours, then every 4 hours) to maintain plasma concentrations within the therapeutic window, avoiding peaks that trigger seizures and troughs that reduce efficacy, thereby minimizing nausea through stable drug levels
Data Source
AI summary
A method of treating pain, e.g., acute post-operative pain, by administering to a human patient(s) a therapeutically effective dose of tramadol intravenously in a dosing regimen which includes one or more loading doses administered at shortened intervals as compared to dosing at steady-state is disclosed. In certain embodiments, the dose of tramadol about 25 mg and the second (and optionally) third doses are intravenously administered at intervals of about 2 hours, and thereafter the tramadol is intravenously administered at a dosing interval of about 4 hours, until the patient no longer requires treatment with tramadol.